Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020-Reference-Cited by-同舟云学术

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Published:2020-06-18 Issue:24 Volume:25 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Percivalle Elena¹,Cambiè Giuseppe²,Cassaniti Irene³¹,Nepita Edoardo Vecchio³¹,Maserati Roberta¹,Ferrari Alessandro³¹,Di Martino Raffaella³¹,Isernia Paola⁴,Mojoli Francesco⁵³,Bruno Raffaele⁶³,Tirani Marcello⁷⁸,Cereda Danilo⁷,Nicora Carlo⁹,Lombardo Massimo¹⁰,Baldanti Fausto³¹

Affiliation:

1. Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy

2. Immunohematology and Transfusion Medicine Unit, Ospedale Maggiore di Lodi, Lodi, Italy

3. Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy

4. SIMT, Centro Lavorazione e Validazione, IRCCS Policlinico San Matteo, Pavia, Italy

5. ICU1 Department of Intensive Medicine, IRCCS Policlinico San Matteo, Pavia, Italy

6. Infectious Diseases I, Department of Medical Sciences and Infectious Diseases, IRCCS Policlinico San Matteo, Pavia, Italy

7. Lombardy Region, Directorate General for Health, UO Prevenzione, Milan, Italy

8. Health Protection Agency of Pavia, Department of Hygiene and Preventive Medicine, Pavia, Italy

9. Chief Executive Office, IRCCS Policlinico San Matteo, Pavia, Italy

10. Chief Executive Office, ASST Lodi, Lodi, Italy

Abstract

We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 − when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19–70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference13 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019.;Zhu;N Engl J Med,2020

2. World Health Organization (WHO). Novel coronavirus – China. Geneva: WHO; 12 Jan 2020. [Accessed 19 Jan 2020]. Available from: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/

3. Coronavirus Disease 2019 (COVID-19) in Italy.;Livingston;JAMA,2020

4. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.;Ye;J Med Virol,2020

5. Deployment of convalescent plasma for the prevention and treatment of COVID-19.;Bloch;J Clin Invest,2020

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January–December 2020;BMJ Open;2023-11

2. Do variations in anomalous mortality in Europe in fall and winter of 2019–2020 tell us anything on the timing of SARS‐CoV‐2 outbreak?;Population, Space and Place;2023-10-31

3. Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers;mBio;2023-10-31

4. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice;Microbiology Spectrum;2023-06-15

5. Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020–November 2021);European Journal of Public Health;2023-06-13